MedTrace Logo

Neuregulin-1 in Patient With Different Forms of Cardiovascular Diseases: a Pilot Study

NCT04391491 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 100

Last updated 2023-05-03

No results posted yet for this study

Summary

This is an observational study of Neuregulin-1 (NRG-1) plasma levels in patients with different forms of cardiovascular disease including microvascular angina (MVA), heart failure with preserved ejection fraction (HFpEF), as well as, heart failure with reduced ejection fraction (HFrEF) and pulmonary hypertension (PH). Investigators intend to identify cardiovascular diseases which are characterized by increased circulating NRG-1, considered to be a biomarker of therapeutic potential of NRG-1. Participants will undergo blood sampling over 3 days following randomisation. Patients demographics and clinical characteristics will be recorded and their associations with NRG-1 will be analysed.

Conditions

Interventions

DIAGNOSTIC_TEST

Neuregulin-1β level in plasma

Peripheral blood will be collected after randomization (plus or minus 3 days), the plasma will be assayed for neuregulin-1b, biomarkers of inflammation and fibrosis, NTproBNP

Sponsors & Collaborators

  • Universiteit Antwerpen

    collaborator OTHER

  • University of Basel

    collaborator OTHER

  • I.M. Sechenov First Moscow State Medical University

    lead OTHER

Principal Investigators

  • Anastasia Shchendrygina · I.M. Sechenov First Moscow State Medical University (Sechenov University)

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-03-01
Primary Completion
2022-12-01
Completion
2023-02-01

Countries

  • Russia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04391491 on ClinicalTrials.gov